The stock of Hookipa Pharma Inc (NASDAQ: HOOK) has decreased by -1.02 when compared to last closing price of 0.71. Despite this, the company has experienced a -12.70% fall in its stock price over the last five trading sessions. globenewswire.com reported 2024-06-04 that NEW YORK and VIENNA, June 04, 2024 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced positive updated results from its Phase 2 clinical trial of HB-200 in combination with pembrolizumab in patients with recurrent/metastatic human papillomavirus 16 positive (HPV16+) head and neck cancer.
Is It Worth Investing in Hookipa Pharma Inc (NASDAQ: HOOK) Right Now?
HOOK has 36-month beta value of 0.82. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for HOOK is 77.61M, and currently, short sellers hold a 0.66% ratio of that float. The average trading volume of HOOK on June 19, 2024 was 853.00K shares.
HOOK’s Market Performance
The stock of Hookipa Pharma Inc (HOOK) has seen a -12.70% decrease in the past week, with a -13.39% drop in the past month, and a -3.96% fall in the past quarter. The volatility ratio for the week is 7.51%, and the volatility levels for the past 30 days are at 9.04% for HOOK. The simple moving average for the past 20 days is -13.56% for HOOK’s stock, with a 3.43% simple moving average for the past 200 days.
Analysts’ Opinion of HOOK
Many brokerage firms have already submitted their reports for HOOK stocks, with BofA Securities repeating the rating for HOOK by listing it as a “Underperform.” The predicted price for HOOK in the upcoming period, according to BofA Securities is $0.50 based on the research report published on December 02, 2022 of the previous year 2022.
Morgan Stanley gave a rating of “Equal-Weight” to HOOK, setting the target price at $6 in the report published on November 12th of the previous year.
HOOK Trading at -13.94% from the 50-Day Moving Average
After a stumble in the market that brought HOOK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.50% of loss for the given period.
Volatility was left at 9.04%, however, over the last 30 days, the volatility rate increased by 7.51%, as shares sank -17.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.92% lower at present.
During the last 5 trading sessions, HOOK fell by -12.70%, which changed the moving average for the period of 200-days by +7.82% in comparison to the 20-day moving average, which settled at $0.8093. In addition, Hookipa Pharma Inc saw -12.81% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HOOK starting from Kandera Reinhard, who purchase 7,000 shares at the price of $0.72 back on Aug 21 ’23. After this action, Kandera Reinhard now owns 43,092 shares of Hookipa Pharma Inc, valued at $5,075 using the latest closing price.
Kandera Reinhard, the Chief Financial Officer of Hookipa Pharma Inc, purchase 8,000 shares at $0.71 during a trade that took place back on Aug 16 ’23, which means that Kandera Reinhard is holding 36,092 shares at $5,712 based on the most recent closing price.
Stock Fundamentals for HOOK
Current profitability levels for the company are sitting at:
- -0.93 for the present operating margin
- 0.94 for the gross margin
The net margin for Hookipa Pharma Inc stands at -0.89. The total capital return value is set at -0.43. Equity return is now at value -50.55, with -30.76 for asset returns.
Based on Hookipa Pharma Inc (HOOK), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -12.96. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -504.0.
Currently, EBITDA for the company is -81.38 million with net debt to EBITDA at 1.99. When we switch over and look at the enterprise to sales, we see a ratio of -0.35. The receivables turnover for the company is 1.74for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.50.
Conclusion
To put it simply, Hookipa Pharma Inc (HOOK) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
